With DARPA’s support to repurpose existing FDA-approved drugs during the early stage of the COVID-19 pandemic, we adopted a novel strategy utilizing MDS to analyze dynamic mechanical changes in the SARS-CoV-2 S protein that are necessary for membrane fusion and viral entry. The gene discussed is PROS1; the disease is COVID-19.